News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
589,928 Results
Type
Article (40202)
Company Profile (90)
Press Release (549634)
Multimedia
Podcasts (128)
Webinars (23)
Section
Business (175009)
Career Advice (2194)
Deals (28825)
Drug Delivery (101)
Drug Development (62158)
Employer Resources (150)
FDA (14107)
Job Trends (12677)
News (286518)
Policy (27284)
Tag
Academia (2204)
Academic (1)
Accelerated approval (17)
Adcomms (20)
Allergies (103)
Alliances (45166)
ALS (134)
Alzheimer's disease (1388)
Antibody-drug conjugate (ADC) (206)
Approvals (14303)
Artificial intelligence (446)
Autoimmune disease (99)
Automation (30)
Bankruptcy (268)
Best Places to Work (9937)
BIOSECURE Act (15)
Biosimilars (145)
Biotechnology (64)
Bladder cancer (124)
Brain cancer (42)
Breast cancer (512)
Cancer (3769)
Cardiovascular disease (308)
Career advice (1872)
Career pathing (32)
CAR-T (219)
CDC (58)
Cell therapy (597)
Cervical cancer (29)
Clinical research (52269)
Collaboration (1359)
Company closure (5)
Compensation (513)
Complete response letters (31)
COVID-19 (2769)
CRISPR (72)
C-suite (591)
Cystic fibrosis (107)
Data (4801)
Decentralized trials (2)
Denatured (38)
Depression (105)
Diabetes (392)
Diagnostics (6777)
Digital health (31)
Diversity (6)
Diversity, equity & inclusion (43)
Drug discovery (196)
Drug pricing (153)
Drug shortages (27)
Duchenne muscular dystrophy (174)
Earnings (76450)
Editorial (55)
Employer branding (20)
Employer resources (136)
Events (89162)
Executive appointments (811)
FDA (16439)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (3)
Frontotemporal dementia (19)
Funding (1126)
Gene editing (147)
Generative AI (43)
Gene therapy (477)
GLP-1 (790)
Government (4191)
Grass and pollen (6)
Guidances (356)
Healthcare (15557)
HIV (46)
Huntington's disease (32)
IgA nephropathy (58)
Immunology and inflammation (193)
Immuno-oncology (31)
Indications (70)
Infectious disease (3019)
Inflammatory bowel disease (145)
Inflation Reduction Act (14)
Influenza (108)
Intellectual property (163)
Interviews (400)
IPO (13130)
IRA (44)
Job creations (3088)
Job search strategy (1552)
Kidney cancer (12)
Labor market (64)
Layoffs (467)
Leadership (33)
Legal (6753)
Liver cancer (69)
Longevity (10)
Lung cancer (506)
Lymphoma (297)
Machine learning (29)
Management (52)
Manufacturing (595)
MASH (136)
Medical device (10893)
Medtech (10925)
Mergers & acquisitions (16527)
Metabolic disorders (959)
Multiple sclerosis (125)
NASH (15)
Neurodegenerative disease (249)
Neuropsychiatric disorders (62)
Neuroscience (2302)
NextGen: Class of 2025 (5268)
Non-profit (3816)
Now hiring (36)
Obesity (426)
Opinion (283)
Ovarian cancer (130)
Pain (139)
Pancreatic cancer (161)
Parkinson's disease (205)
Partnered (28)
Patents (350)
Patient recruitment (297)
Peanut (45)
People (48887)
Pharmaceutical (21)
Pharmacy benefit managers (20)
Phase I (16088)
Phase II (22500)
Phase III (18165)
Pipeline (3557)
Policy (257)
Postmarket research (2181)
Preclinical (6855)
Press Release (70)
Prostate cancer (217)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (620)
Real estate (4897)
Recruiting (60)
Regulatory (19653)
Reports (37)
Research institute (2049)
Resumes & cover letters (338)
Rett syndrome (22)
RNA editing (12)
RSV (80)
Schizophrenia (120)
Series A (189)
Series B (138)
Service/supplier (6)
Sickle cell disease (79)
Special edition (21)
Spinal muscular atrophy (126)
Sponsored (41)
Startups (2906)
State (1)
Stomach cancer (13)
Supply chain (78)
Tariffs (75)
The Weekly (88)
Vaccines (1102)
Venture capital (64)
Weight loss (285)
Women's health (60)
Worklife (17)
Date
Today (74)
Last 7 days (430)
Last 30 days (1953)
Last 365 days (25381)
2025 (25114)
2024 (28637)
2023 (32567)
2022 (42848)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28965)
2017 (27347)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (851)
Alabama (72)
Alaska (6)
Arizona (217)
Arkansas (9)
Asia (33728)
Australia (5867)
California (8190)
Canada (2532)
China (749)
Colorado (376)
Connecticut (399)
Delaware (244)
Europe (80322)
Florida (1276)
Georgia (279)
Idaho (43)
Illinois (627)
India (54)
Indiana (410)
Iowa (18)
Japan (339)
Kansas (102)
Kentucky (34)
Louisiana (17)
Maine (78)
Maryland (1092)
Massachusetts (5991)
Michigan (299)
Minnesota (436)
Mississippi (4)
Missouri (96)
Montana (28)
Nebraska (21)
Nevada (102)
New Hampshire (60)
New Jersey (2457)
New Mexico (28)
New York (2261)
North Carolina (1140)
North Dakota (9)
Northern California (3930)
Ohio (259)
Oklahoma (19)
Oregon (28)
Pennsylvania (1664)
Puerto Rico (6)
Rhode Island (36)
South America (1060)
South Carolina (40)
Southern California (3196)
Tennessee (136)
Texas (1311)
United States (30180)
Utah (281)
Vermont (1)
Virginia (206)
Washington D.C. (68)
Washington State (672)
West Virginia (4)
Wisconsin (95)
Wyoming (2)
589,928 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Radiopharmaceuticals
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
November 6, 2025
·
5 min read
·
Annalee Armstrong
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.
December 9, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data room and moving on to a capital raise.
November 25, 2025
·
3 min read
·
Annalee Armstrong
Approvals
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford Medicine professor called a “game changing advance” for the field.
November 25, 2025
·
3 min read
·
Heather McKenzie
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets;
BioSpace
takes a look at how the FDA is functioning mid-shutdown.
October 29, 2025
·
1 min read
·
Heather McKenzie
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in Sjögren’s disease, the pharma reported at the American College of Rheumatology Convergence congress on Wednesday.
October 29, 2025
·
3 min read
·
Heather McKenzie
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity’s neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.
October 26, 2025
·
2 min read
·
Heather McKenzie
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives a notable drop in COVID-19 sales.
December 16, 2025
·
3 min read
·
Annalee Armstrong
1 of 58,993
Next